Express Sees Q3 Comparable Sales Down Mid-Single Digits

Third Quarter 2022 The Company expects the following for the third quarter of 2022 compared to the third quarter of 2021: Comparable sales to decrease mid-single digits Gross margin rate to

Third Quarter 2022

The Company expects the following for the third quarter of 2022 compared to the third quarter of 2021:

  • Comparable sales to decrease mid-single digits
  • Gross margin rate to decrease approximately 350 basis points
  • SG&A expenses as a percent of sales to delever approximately 350 basis points, including incremental investments in technology and higher store labor expenses
  • Net interest expense of $4 million
  • Effective tax rate essentially zero percent
Total
0
Shares
Related Posts
Read More

Lyra Therapeutics Reports Topline Results From Phase 3 ENLIGHTEN 1 Trial For LYR-210 in Chronic Rhinosinusitis; ENLIGHTEN 1 Trial Did Not Meet Its Primary Endpoint; Company Plans To Evaluate Full Dataset And Path Forward

ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forwardWATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the

LYRA